Zobrazeno 1 - 10
of 515
pro vyhledávání: '"WENBIN QIAN"'
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-14 (2024)
Abstract Objectives Immune regulation is a pivotal factor in the pathogenesis and repair of spinal cord injury (SCI). This study aims to explore potential immune center genes associated with spinal cord injury. Methods The public data set GSE151371 w
Externí odkaz:
https://doaj.org/article/bcb8428fb1614772b8e3129d8a221a2f
Autor:
Xubo Gong, Lianjun Zhang, Xin He, Jing Yang, Xiang Li, Weiwei Liu, Bin Zhang, Zhihua Tao, Wenbin Qian
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-4 (2024)
Abstract Natural killer (NK) cell-based therapies have made great progress in treating both hematological and solid tumors. Their unique mechanism of action does not rely on antigen presentation to recognize and eliminate tumor cells, making them a p
Externí odkaz:
https://doaj.org/article/5aca4f5190264219b91e460327579337
Publikováno v:
European Physical Journal C: Particles and Fields, Vol 84, Iss 3, Pp 1-14 (2024)
Abstract Decay-time-dependent $$C\!P$$ C P -violation effects in transitions of neutral B mesons to $$C\!P$$ C P -eigenstates can be visualised by oscillations in the asymmetry, as a function of decay time, between decay yields from mesons tagged as
Externí odkaz:
https://doaj.org/article/f5e1d002774149da825d560836282a11
Autor:
Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao, Wenbin Qian
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-4 (2024)
Abstract Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venetoclax (VEN) with hypomethylating agents has been establ
Externí odkaz:
https://doaj.org/article/d7b962c32d33430392972de756f9ddc6
Autor:
Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang, Jianda Hu, Huaqing Wang, Hang Su, Zhengming Jin, Wenbin Qian, Chuan Jin, Mingzhi Zhang, Ding Yu, Li Liu, Guoan Chen, Yarong Li, Tao Sun, Jie Jin, Huizheng Bao, Xin Du, Hui Zhou, Gan Fu, Yuankai Shi
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results f
Externí odkaz:
https://doaj.org/article/7eecafad55844bb3b801aa99db2e8a55
Autor:
Wen Lei, Ai Zhao, Hui Liu, Chunmei Yang, Cheng Wei, Shanshan Guo, Zhilu Chen, Qunyi Guo, Linjie Li, Mingzhe Zhao, Gongqiang Wu, Guifang Ouyang, Ming Liu, Jinyi Zhang, Jimin Gao, Wenbin Qian
Publikováno v:
Cell Discovery, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract Although CD19-specific chimeric antigen receptor (CAR) T cells are curative for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), disease relapse with tumor antigen-positive remains a challenge. Cytokine/chemokine-expres
Externí odkaz:
https://doaj.org/article/cfcb19c9c9bd4e5d8b7f347d75b7e0b5
Autor:
Xibin Xiao, Hui Liu, Xi Qiu, Panpan Chen, Xian Li, Dan Wang, Guangrong Song, Yu Cheng, Liming Yang, Wenbin Qian
Publikováno v:
EClinicalMedicine, Vol 70, Iss , Pp 102516- (2024)
Summary: Background: Current approved chimeric antigen receptor (CAR) T-cell products are autologous cell therapies that are costly and poorly accessible to patients. We aimed to evaluate the safety and antitumor activity of a novel off-the-shelf ant
Externí odkaz:
https://doaj.org/article/b512e7d9c07d48418b69c8a8da281490
Autor:
Xiuyong Dang, Ping Li, Aijun Shen, Yan Lu, Zeyu Zhu, Min Zhang, Wenbin Qian, Aibin Liang, Wenjun Zhang
Publikováno v:
Cancer Medicine, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Introduction Chimeric antigen receptor (CAR) T cell therapy has markedly improved the prognosis of patients with diffuse large B‐cell lymphoma (DLBCL). The relative positioning of tumor lesions in lymphoma varies among patients, manifestin
Externí odkaz:
https://doaj.org/article/c80be8370a8e431c846692870f6dcbcf
Autor:
Xibin Xiao, Panpan Chen, Yadi Zhong, Xiu Luo, Yao Liu, Ying Lu, Xueli Jin, Wenbin Qian, Weidong Han, Aibin Liang, Hui Liu
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20838-20846 (2023)
Abstract Background Little was known on infection and mortality rates, still less the risk factors of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) omicron variant in B‐cell lymphoma patients following CD19 targeted chimeric anti
Externí odkaz:
https://doaj.org/article/f5026182ec124d3ca8d1cfaed7a5af7e
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 9, Pp 646-661 (2023)
Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an ability to elicit curative effects via systemic administration. Tumor cells often create an unfavorable immunosuppressive microenvironment that degrade viral str
Externí odkaz:
https://doaj.org/article/08f866ed913c47c39327cb7e83a7e90a